On April 24, 1997, the Company acquired all of the outstanding stock of Vascular Targeting Technologies, Inc. (formerly known as Peregrine Pharmaceuticals, Inc.) in exchange for 5,080,000 shares of the Company's common stock and the assumption of
...
more